The Experts below are selected from a list of 4626 Experts worldwide ranked by ideXlab platform
Jaime Robledo - One of the best experts on this subject based on the ideXlab platform.
-
Ertapenem resistance in 2 tertiary-care hospitals: Microbiology, Epidemiology, and risk factors.
Enfermedades infecciosas y microbiologia clinica (English ed.), 2017Co-Authors: Natalia Maldonado, Bibiana Castro, Indira Berrio, Miguel Manjarrés, Carlos Robledo, Jaime RobledoAbstract:Abstract Introduction Carbapenems resistance is a growing phenomenon and a threat to public health because of the reduced therapeutic options for resistant infections. Methods A retrospective case–control study was conducted in 2 tertiary-care hospitals in Medellin, Colombia. Fifty patients infected with ertapenem-resistant enterobacteriaceae were compared with a control group consisting of 100 patients with infections caused by ertapenem susceptible enterobacteriaceae. A multivariate logistic regression model was used to identify factors that best explain ertapenem-resistant enterobacteriaceae infections. Results The factors associated with ertapenem-resistant enterobacteriaceae infections were prior exposure to carbapenems (adjusted OR 3.43; 95% IC 1.08–10.87) and prior exposure to cefepime (adjusted OR 6.46; 95% IC 1.08–38.38). Conclusion Prior exposure to antibiotics is the factor that best explains the ertapenem-resistant enterobacteriaceae infection in this population, highlighting the importance of antimicrobial stewardship programs in hospitals.
Kenneth A Katz - One of the best experts on this subject based on the ideXlab platform.
-
sexually acquired syphilis historical aspects Microbiology Epidemiology and clinical manifestations
Journal of The American Academy of Dermatology, 2020Co-Authors: Amy K Forrestel, Carrie L Kovarik, Kenneth A KatzAbstract:Syphilis is caused by infection with the spirochetal bacterium Treponema pallidum subsp. pallidum. It was first recognized in the late 15th century. Since 2000, the incidence of sexually acquired syphilis has increased substantially in the developed world, with men who have sex with men and persons living with HIV infection disproportionately affected. Clinical manifestations of syphilis are protean and often include mucocutaneous manifestations. The first article in this continuing medical education series reviews historical aspects, Microbiology, Epidemiology, and clinical manifestations of sexually acquired syphilis.
Natalia Maldonado - One of the best experts on this subject based on the ideXlab platform.
-
Ertapenem resistance in 2 tertiary-care hospitals: Microbiology, Epidemiology, and risk factors.
Enfermedades infecciosas y microbiologia clinica (English ed.), 2017Co-Authors: Natalia Maldonado, Bibiana Castro, Indira Berrio, Miguel Manjarrés, Carlos Robledo, Jaime RobledoAbstract:Abstract Introduction Carbapenems resistance is a growing phenomenon and a threat to public health because of the reduced therapeutic options for resistant infections. Methods A retrospective case–control study was conducted in 2 tertiary-care hospitals in Medellin, Colombia. Fifty patients infected with ertapenem-resistant enterobacteriaceae were compared with a control group consisting of 100 patients with infections caused by ertapenem susceptible enterobacteriaceae. A multivariate logistic regression model was used to identify factors that best explain ertapenem-resistant enterobacteriaceae infections. Results The factors associated with ertapenem-resistant enterobacteriaceae infections were prior exposure to carbapenems (adjusted OR 3.43; 95% IC 1.08–10.87) and prior exposure to cefepime (adjusted OR 6.46; 95% IC 1.08–38.38). Conclusion Prior exposure to antibiotics is the factor that best explains the ertapenem-resistant enterobacteriaceae infection in this population, highlighting the importance of antimicrobial stewardship programs in hospitals.
Nigel Curtis - One of the best experts on this subject based on the ideXlab platform.
-
non typhoidal salmonella in children Microbiology Epidemiology and treatment
Advances in Experimental Medicine and Biology, 2013Co-Authors: Gabrielle M Haeusler, Nigel CurtisAbstract:Non-typhoidal Salmonellae (NTS) are an important cause of infectious diarrhoea world-wide. In the absence of immune deficiency, gastroenteritis caused by NTS is usually mild, self limiting and rarely requires intervention. NTS are also an important cause of invasive disease, particularly in developing countries, likely secondary to the high prevalence of co-existing malnutrition, malaria and HIV infection. This review provides an overview of the Microbiology, Epidemiology and pathogenesis of NTS, and compares recommendations for the treatment of NTS gastroenteritis in children.
Leonard H Calabrese - One of the best experts on this subject based on the ideXlab platform.
-
progressive multifocal leukoencephalopathy in rheumatic diseases evolving clinical and pathologic patterns of disease
Arthritis & Rheumatism, 2007Co-Authors: Leonard H Calabrese, Eamonn S Molloy, Deren Huang, Richard M RansohoffAbstract:Progressive multifocal leukoencephalopathy (PML) is a rare, serious, and usually fatal demyelinating disease that occurs predominantly in severely immunosuppressed patient populations. The etiologic agent is the JC virus (JCV), a polyomavirus that is widely distributed as a latent infection in the general population but becomes activated, leading to destruction of myelin-producing oligodendrocytes. Patients who survive this complication are left with devastating neurologic sequelae. PML has been described mainly in patients infected with the human immunodeficiency virus (HIV). However, other immunosuppressed patient populations, including those with malignancies, organ transplants, and systemic lupus erythematosus (SLE) (1–20) and other rheumatic diseases (22–32), are at risk of developing this complication. The appearance of PML in 0.1% of patients treated in clinical trials with the biologic therapeutic agent natalizumab (33,34), an antagonist of 4 integrin, greatly hindered the development of this promising new agent for the treatment of multiple sclerosis (MS), as well as plans for expanded indications for this agent in Crohn’s disease and rheumatoid arthritis (RA), for which it was already in clinical trials. In addition, on December 18, 2006, the US Food and Drug Administration (FDA) in conjunction with Genentech and Biogen Idec, the makers of rituximab, a recently approved biologic agent for the treatment of RA, issued a warning to health care providers, informing them that 2 patients receiving rituximab for the treatment of SLE (an unapproved indication) had developed PML (35). Recent years have witnessed advances in better understanding of the pathologic response to JCV and the pathogenesis of PML (36). An evolving clinical picture is emerging: PML is a protean disease that is difficult to distinguish clinically from immune-mediated diseases of the central nervous system (CNS), such as MS, neuropsychiatric SLE, and vasculitis of the CNS (37,38). Thus, it is timely to review PML. We describe herein the Microbiology, Epidemiology, immunology, and pathology of PML, its changing clinical and pathologic spectrum, recent advances in our understanding of the pathogenesis of PML, and its relevance to physicians treating patients with rheumatic disorders. We report the results of a systematic literature review of all 36 patients with rheumatic diseases who have developed PML, including a previously unreported case in a patient treated at Cleveland Clinic. Nearly two-thirds of the cases of PML occurred in patients with SLE, and many cases of PML in SLE occurred in patients who had had minimal immunosuppression, which raises the possibility that SLE itself may predispose to PML.